AUA 2026: Key Urology Guideline Updates and Clinical Highlights
AUA 2026 focuses on Immuno-Oncology (IO) for Non-Muscle Invasive Bladder Cancer (NMIBC) and Radioligand Therapy (RLT) for metastatic Hormone-Sensitive Prostate Cancer (mHSPC). These clinical shifts signal a transition toward precision ... Read More